The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling

Emmanuel Laplantine, Christine Chable-Bessia, Anne Oudin, Adèle Soria, Peggy Mérida, Manon Gourdelier, S Mestiri, Indira Besseghe, Erwan Brémaud, Aymeric Neyret,

iScience · 2022 · 25 citations · 61 references

DOIFull text

Open access

Concepts

Abstract

Among these, we show that Auranofin prevents post-translational modifications of NF-κB effectors and their recruitment into activating complexes in response to SARS-CoV-2 infection or cytokine stimulation. In addition, we demonstrate that Auranofin counteracts several steps of SARS-CoV-2 infection. First, it inhibits a raft-dependent endocytic pathway involved in SARS-CoV-2 entry into host cells; Second, Auranofin alters the ACE2 mobility at the plasma membrane. Overall, Auranofin should prevent SARS-CoV-2 infection and inflammatory damages, offering new opportunities as a repurposable drug candidate to treat COVID-19.

References

61